It has been demonstrated that GPCRs are deeply involved in mitigating symptoms of schizophrenia, since typical and atypical antipsychotics such as haloperidol and olanzapine have antagonistic activities for the dopamine D2 receptor as well as other multiple GPCRs. This evidence concerns the gene DRD2 and schizophrenia.